What is the recommended dose of rivaroxaban (Xarelto) for deep‑vein thrombosis prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rivaroxaban Dosing for DVT Prophylaxis

For DVT prophylaxis after major orthopedic surgery (hip or knee replacement), rivaroxaban 10 mg once daily is the recommended dose, started 6-10 hours postoperatively and continued for 10-14 days (knee) or up to 35 days (hip). 1

Orthopedic Surgery Prophylaxis

Standard dosing regimen:

  • Dose: 10 mg orally once daily 1, 2
  • Timing: Start 6-10 hours after surgery 1, 2
  • Duration:
    • Total knee arthroplasty: 10-14 days 1
    • Total hip arthroplasty: 28-35 days 3, 1
    • Extended prophylaxis up to 35 days may be considered for high-risk patients 1

This dosing has been shown to be noninferior to LMWH (enoxaparin) in the RECORD trials, with reduced DVT, PE, or death without increased bleeding rates 1.

Important Contraindications and Cautions

Rivaroxaban is contraindicated in:

  • Severe renal insufficiency (CrCl <30 mL/min) 1, 4
  • Severe liver disease with coagulopathy 1
  • Concomitant systemic treatment with strong CYP3A4 and P-glycoprotein inhibitors (azole-antimycotics, HIV protease inhibitors) 2

Use with caution in:

  • Moderate renal impairment (CrCl 30-50 mL/min) 4
  • Elderly patients (>75 years) 3
  • Patients weighing <60 kg 3

Non-Orthopedic Settings

For acutely ill general medical patients: The 2014 CHEST guidelines note that rivaroxaban was noninferior to enoxaparin in the MAGELLAN trial but was associated with higher bleeding risk, and therefore rivaroxaban is NOT recommended for VTE prophylaxis in acutely ill general medical patients 1.

For non-orthopedic surgery patients: Rivaroxaban has not been adequately studied in this population and is not recommended 1.

For cancer patients: Current guidelines do not recommend rivaroxaban for prophylactic anticoagulation in cancer patients due to insufficient data in this population 4.

Key Clinical Pearls

  • No routine coagulation monitoring is required when using rivaroxaban for prophylaxis 2
  • No bridging therapy is needed when initiating rivaroxaban prophylaxis 3
  • Rivaroxaban should be taken with food when used at higher treatment doses (15-20 mg), though the 10 mg prophylactic dose can be taken with or without food 5
  • The drug has a half-life of 5-9 hours in younger patients and 11-13 hours in elderly patients 4
  • Drug interactions are critical: Carbamazepine and other strong CYP3A4 inducers significantly decrease rivaroxaban levels and should be avoided 6

Common Pitfall

A critical error is using rivaroxaban 10 mg daily for treatment of acute DVT—this is a prophylactic dose only. For acute DVT treatment, the correct regimen is rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily 5, 7. Do not confuse prophylaxis dosing (10 mg daily) with treatment dosing.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.